Pneumoconiosis Market Report 2026

The pneumoconiosis market size has grown strongly in recent years. It will grow from $5.59 billion in 2025 to $6.04 billion in 2026 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to increasing prevalence of occupational lung diseases, long-term exposure to industrial dust particles, expansion of mining and construction activities, limited early-stage diagnostic capabilities, rising awareness of workplace respiratory risks.

The pneumoconiosis market size is expected to see strong growth in the next few years. It will grow to $8.15 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing implementation of preventive screening programs, rising investments in advanced pulmonary diagnostics, growing focus on occupational safety compliance, expansion of personalized respiratory care approaches, increasing research into fibrosis management therapies. Major trends in the forecast period include increasing adoption of advanced diagnostic imaging techniques, rising focus on early disease detection programs, growing use of long-term oxygen therapy solutions, expansion of occupational health monitoring initiatives, enhanced emphasis on pulmonary rehabilitation services.

The high prevalence of smoking is expected to drive the growth of the pneumoconiosis market going forward. Smoking involves inhaling and exhaling smoke from burning tobacco products such as cigarettes, cigars, or pipes, which release harmful chemicals that adversely affect lung function, cardiovascular health, and overall well being. The increasing prevalence of smoking is linked to rising nicotine dependence and continued tobacco use among certain age groups. Higher smoking rates contribute to the burden of pneumoconiosis by increasing the incidence of smoking related lung diseases. For instance, in June 2023, according to The Guardian, a UK based news organization, 11.8% of individuals aged 14 to 17 reported vaping in 2022, which increased to 14.5% in early 2023. Therefore, the high prevalence of smoking is contributing to the growth of the pneumoconiosis market.

Rising healthcare expenditures are expected to support the growth of the pneumoconiosis market. Healthcare expenditures represent the total spending on medical services, treatments, and healthcare related products by individuals, governments, and organizations. The increase in healthcare spending is largely driven by the growing prevalence of chronic diseases that require long term treatment and management. Higher healthcare expenditures facilitate pneumoconiosis treatment by supporting early diagnosis, ongoing medical care, respiratory therapies, and access to specialized treatments and medications that help control symptoms, slow disease progression, and improve patient quality of life. For instance, in May 2023, the Office for National Statistics, a UK based statistics authority, reported that healthcare spending in the UK reached approximately $362.08 billion (£292 billion) in 2023, reflecting a nominal increase of 5.6%. Additionally, healthcare expenditure as a share of gross domestic product declined slightly to 10.9% in 2023 from 11.1% in 2022. Therefore, rising healthcare expenditures are driving the growth of the pneumoconiosis market.

Major organizations operating in the pneumoconiosis market are focusing on technological innovations, such as AI based portable diagnostic devices, to improve early detection of silicosis and pneumoconiosis, expand screening coverage, enhance diagnostic accuracy, and reduce dependence on limited radiology expertise. AI based portable diagnostic devices utilize deep learning algorithms to analyze chest X ray images and automatically identify lung regions with potential pneumoconiosis related abnormalities, enabling faster and more reliable diagnosis while minimizing human error. For instance, in November 2023, Malviya National Institute of Technology (MNIT), an India based public technical university, launched the SILICO AI portable device for pneumoconiosis screening. This device enables rapid on site analysis of chest X rays among dust exposed populations, improving early detection and allowing timely medical intervention compared with conventional manual X ray interpretation, which is slower, resource intensive, and subject to variability among readers.

Major companies operating in the pneumoconiosis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Eli Lilly and Co., Boehringer Ingelheim, Mylan Pharmaceuticals, Bristol Myers Squibb, Sino Biopharmaceutical Limited, Aurobindo Pharmaceuticals, Hikma Pharmaceuticals plc, Veracyte Inc., Lupin, GlaxoSmithKline plc, AstraZeneca plc, Novartis AG, Sanofi SA, Cipla Ltd, Sun Pharmaceutical Industries Ltd, Dr Reddys Laboratories Ltd, Teva Pharmaceutical Industries Ltd, Chiesi Farmaceutici S.p.A., Orion Corporation.

North America was the largest region in the pneumoconiosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumoconiosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pneumoconiosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the pneumoconiosis market by increasing the cost of imported diagnostic imaging equipment, respiratory devices, oxygen delivery systems, and specialized medical consumables used in disease diagnosis and management. Hospitals and diagnostic centers in North America and Europe are most affected due to reliance on imported imaging and respiratory care technologies, while Asia-Pacific faces rising costs for diagnostic infrastructure expansion. These tariffs are increasing treatment and monitoring costs and placing pressure on healthcare budgets. However, they are also encouraging domestic manufacturing of respiratory equipment and fostering localized production of diagnostic devices, improving long-term supply resilience.

The pneumoconiosis market research report is one of a series of new reports that provides pneumoconiosis market statistics, including pneumoconiosis industry global market size, regional shares, competitors with a pneumoconiosis market share, detailed pneumoconiosis market segments, market trends and opportunities, and any further data you may need to thrive in the pneumoconiosis industry. This pneumoconiosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pneumoconiosis is a group of lung diseases that result from the long term inhalation of certain types of dust, leading to inflammation and scarring of lung tissue. This lung damage reduces the ability of the lungs to exchange oxygen efficiently, causing symptoms such as shortness of breath, coughing, and reduced exercise capacity.

The primary types of pneumoconiosis include asbestosis, berylliosis, byssinosis, coal workers pneumoconiosis, silicosis, and others. Asbestosis is a chronic lung disease caused by prolonged exposure to asbestos fibers. Available treatment options include medications, oxygen therapy, pulmonary rehabilitation, and other supportive therapies. Routes of administration include oral, inhalational, and others, with diagnostic approaches such as chest X ray, computed tomography scans, lung function tests, and bronchoscopy. These services are utilized across hospitals, specialty clinics, diagnostic centers, and other healthcare settings.

The pneumoconiosis market consists of sales of protective equipment, diagnostic imaging systems, and therapeutic drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.